Thought this deserves a thread all of its own.
I asked ChatGPT:
what are the top 40 inflammation reducing drugs and their cytokine target?
ChatGPT responded:
Here’s a comprehensive list of 40 inflammation-reducing drugs along with their primary cytokine targets where applicable. These drugs target various cytokines involved in inflammatory processes:
- Adalimumab (Humira) - TNF-alpha inhibitor
- Infliximab (Remicade) - TNF-alpha inhibitor
- Etanercept (Enbrel) - TNF-alpha inhibitor
- Certolizumab pegol (Cimzia) - TNF-alpha inhibitor
- Golimumab (Simponi) - TNF-alpha inhibitor
- Anakinra (Kineret) - IL-1 receptor antagonist
- Canakinumab (Ilaris) - IL-1β inhibitor
- Rilonacept (Arcalyst) - IL-1 inhibitor (IL-1α and IL-1β)
- Tocilizumab (Actemra) - IL-6 receptor inhibitor
- Sarilumab (Kevzara) - IL-6 receptor inhibitor
- Sirukumab (no longer marketed) - IL-6 inhibitor
- Secukinumab (Cosentyx) - IL-17A inhibitor
- Ixekizumab (Taltz) - IL-17A inhibitor
- Brodalumab (Siliq) - IL-17 receptor inhibitor
- Ustekinumab (Stelara) - IL-12/IL-23 inhibitor
- Risankizumab (Skyrizi) - IL-23 inhibitor
- Guselkumab (Tremfya) - IL-23 inhibitor
- Abatacept (Orencia) - T cell co-stimulation blocker (inhibits IL-2)
- Methotrexate - Folate antagonist (exact cytokine target varies)
- Leflunomide (Arava) - Pyrimidine synthesis inhibitor (exact cytokine target varies)
- Sulfasalazine - NF-kB inhibitor (exact cytokine target varies)
- Hydroxychloroquine - Antimalarial (exact cytokine target varies)
- Colchicine - Inhibits microtubule polymerization (exact cytokine target varies)
- Prednisone - Glucocorticoid (broad anti-inflammatory effects)
- Dexamethasone - Glucocorticoid (broad anti-inflammatory effects)
- Budesonide - Glucocorticoid (broad anti-inflammatory effects)
- Tacrolimus (Prograf) - Calcineurin inhibitor (inhibits IL-2)
- Cyclosporine (Neoral) - Calcineurin inhibitor (inhibits IL-2)
- Azathioprine (Imuran) - Purine synthesis inhibitor (exact cytokine target varies)
- Mycofenolate mofetil (CellCept) - Inosine monophosphate dehydrogenase inhibitor (exact cytokine target varies)
- Apremilast (Otezla) - Phosphodiesterase-4 inhibitor (regulates multiple cytokines)
- Janus Kinase (JAK) Inhibitors:
- Tofacitinib (Xeljanz) - JAK1 and JAK3 inhibitor
- Baricitinib (Olumiant) - JAK1 and JAK2 inhibitor
- Upadacitinib (Rinvoq) - JAK1 inhibitor
- Dupilumab (Dupixent) - IL-4 and IL-13 inhibitor
- Benralizumab (Fasenra) - IL-5 receptor antagonist
- Mepolizumab (Nucala) - IL-5 inhibitor
- Reslizumab (Cinqair) - IL-5 inhibitor
- Omalizumab (Xolair) - IgE antibody (modulates allergic response)
- Belimumab (Benlysta) - BLyS-specific inhibitor (modulates B cell activation)
- Etokimab (not widely approved) - IL-33 inhibitor
- Rituximab (Rituxan) - CD20 antibody (targets B cells, which can produce inflammatory cytokines)
These drugs are utilized in various autoimmune diseases, inflammatory conditions, and allergic disorders. They work by modulating specific cytokines, receptors, or cellular pathways involved in the inflammatory response, thereby reducing inflammation and associated symptoms.